Drugs / H7N9 pIIV
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03581903 | Sep 2017 → Sep 2018 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT02957656 | Dec 2016 → Jun 2018 | — | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | H7N9 pIIV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03581903 ↗ |
| Modality | Vaccine | “AS03-adjuvanted H7N9 pandemic inactivated influenza vaccine (H7N9 pIIV)” NCT02957656 ↗ |
| Route | Intramuscular | “Administered by intramuscular injection in the deltoid.” NCT02957656 ↗ |